应用新的B超检查参数测量随访脉络膜转移癌的变化(英文)

A new parameter of ultrasonic measurement for follow-up of choroidal metastasis

目的:报道应用新的B超检查参数(最大交叉截面积)测量评估随访患者的脉络膜转移肿瘤的大小。方法:报告1例脉络膜转移癌患者,在随访中应用B超测量其肿瘤的高、基底和最大交叉截面积。结果:一位62岁华人老年妇女,已知为肺非小细胞癌患者,表现为右眼无痛性视物模糊。被诊为双眼脉络膜转移癌(右眼进展期,左眼初期),双眼视力良好。首次化疗后右眼肿瘤明显减小,但最后一轮化疗结束后6wk即出现增长。患者又进行了放疗和另一轮的化疗后右眼肿瘤大小没有变化。左眼肿瘤大小在随后的2a内没有变化。双眼维持着最佳矫正视力(右6/9,左6/6)。对右眼肿瘤的大小进行了连续B超测量评估。结论:超声检测在随访中是可重复的,并与右眼肿瘤临床表现相符。我们建议在治疗阶段应用B超对脉络膜肿瘤的大小进展或转归进行定量评估。

AIM： To report the usefulness of a new parameter （maximum cross sectional area） in the measurements of B-scan ultrasonography to evaluate the progress of choroidal metastatic tumour size during the follow-up of patient. METHODS： Case report-the B-scan ultrasonographic measurements of height, base and maximum cross sectional area during the follow-up of the patient are presented. RESULTS： A 62-year-old Chinese lady, known case of non-small cell lung carcinoma, presented with painless blurring of vision in the right eye. She was diagnosed to have bilateral choroidal metastasis （advanced in the right eye and early in the left eye） with good vision in both eyes. The tumour size in the right eye reduced significantly after the first chemotherapy; but increased again 6 weeks after the end of last cycle of chemotherapy. She was given radiotherapy and another course of chemotherapy. The tumour size in the right eye did not respond much later on. However, the tumour size in the left eye was static through out the follow up period of 2 years. The patient maintained best corrected visual acuity in both eyes （6/9 in right eye and 6/6 in left eye）. The progress of tumour size in right eye was evaluated with serial B-scan ultrasonographic measurements. CONCLUSION： The ultrasonographic measurements were reproducible all through the follow up period and coincided well with clinical appearance of the tumour in right eye. We suggest the use of B-scan ultrasonography in the follow up of patients with elevated choroidal masses for quantitative assessment of progression/regression in their size during the treatment period.